Transparency International Germany vs. Ratiopharm

الادعاءات

Ratiopharm, a pharmaceuticals company and major producer of generic drugs, has allegedly engaged in unethical marketing practices, including bribing doctors and pharmacists in Belgium, Canada, Spain, Estonia and Germany.

المبادئ التوجيهية ذات الصلة لمنظمة التعاون والتنمية في الميدان الاقتصادي

• المجلد 2000 الفصل الثالث
• Version 2000 Chapter IX
• Version 2000 Chapter VI
• Version 2000 Chapter VII

النتيجة

In December 2006, the German NCP rejected the second complaint against Ratiopharm. The NCP argued that the complaint would had to be dealt with by the NCP of the country where the alleged misbehaviour occurred, i.e. Belgium, Canada, Estonia, and Spain.

Transparency International and the NCP met informally in March 2007. Again, the NCP insisted it could not accept the Ratiopharm case and refused to forward it to the relevant NCPs. The NCP claimed its “hands were tied”.

Transparency International maintains that the alleged misbehaviour emanates from Ratiopharm’s German headquarters to other countries. Therefore, the German NCP should take the lead in handling the complaint. In addition, the NCP’s refusal to forward the case to the other relevant NCPs inspires little faith in the NCP’s offer to assist informally.

تفاصيل إضافية

شكاوى أخرى

• Gresea & Transparency International Germany vs Ratiopharm
• Transparency International Germany vs. Ratiopharm

الأوراق

• بيان صحفي

  13 March 2007

  Article by TI’s Shirley van Buiren concerning the difficult dealings with the German NCP.

  Transparency International Germany
• reject

  1 December 2006

  In December 2006, the German NCP rejected the second complaint against Ratiopharm, arguingthat the complaint would have to be dealt with by the NCPs of the countries where the alleged misbehaviour occurred, i.e. Belgium, Canada, Estonia, and Spain.

  NCP ألمانيا
• رسالة

  19 July 2006

  NCP acknowledges receipt of the revised complaint.

  NCP ألمانيا
• ملف

  18 July 2006

  Second complaint filed with German NCP. The first complaint was rejected, because according to the NCP, it only concerned Ratiopharm’s activities in Germany.

  Transparency International Germany